Protagonist Therapeutics, Inc.: Revision history

20 August 2022

• curprev 14:1014:10, 20 August 2022 95.149.241.133 talk 938 bytes +11 No edit summary undo

13 August 2022

• curprev 21:2121:21, 13 August 2022 109.180.50.163 talk 927 bytes +15 No edit summary undo

30 July 2022

• curprev 22:1022:10, 30 July 2022 >Chris 912 bytes +912 Created page with "Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha..."